Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
Rhea-AI Summary
Regentis Biomaterials (NYSE American: RGNT) priced its initial public offering of 1,250,000 ordinary shares at $8.00 per share, for aggregate gross proceeds of $10,000,000, with a 45-day underwriter option to purchase up to an additional 187,500 shares. The Ordinary Shares are expected to begin trading on December 4, 2025, and the Offering is expected to close on or about December 5, 2025, subject to customary closing conditions.
The company intends to use net proceeds primarily for development activities, including completing its pivotal trial and preparing the PMA submission for GerlinC, and for corporate purposes including repayment of certain debt and deferred compensation. ThinkEquity is sole book-running manager.
Positive
- Gross proceeds of $10.0M from the IPO
- Proceeds earmarked for pivotal trial completion and PMA preparation
- Listing expected on NYSE American on Dec 4, 2025
Negative
- Underwriters have a 45-day option for up to 187,500 shares (potential dilution)
- Proceeds stated before underwriting discounts and offering expenses
Insights
Regentis priced a $10.0M IPO to fund a pivotal trial and PMA preparation, providing near-term financing for clinical and corporate needs.
The company sold 1,250,000 ordinary shares at
The financing directly addresses near-term cash needs tied to regulatory milestones. Key dependencies include the pace and cost of the pivotal trial and the PMA submission timeline; any delays or higher-than-expected trial costs could require additional funding. Watch the closing confirmation around
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at an initial public offering price of
The Ordinary Shares are expected to begin trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”. The Offering is expected to close on or about December 5, 2025, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and deferred compensation payments.
ThinkEquity is acting as sole book-running manager for the Offering.
A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares being sold in the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective, as amended, on November 12, 2025. The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus and the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The preliminary prospectus was filed with the SEC and is available, and the final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. GelrinC is Regentis’ cartilage injury therapeutic based on a unique hydrogel, erodible and resorbable, matrix of polyethylene glycol. The Company’s lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into a temporary implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device with a Conformité Européene mark in Europe, (CE mark number 3900600CE02). The Company plans to start commercialization efforts in Europe to bring its product to market, while being focused in parallel on completing its pivotal study for obtaining United States Food and Drug Administration approval. For more information, please visit https://www.regentis.co.il/
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include the expected start of trading of the Ordinary Shares on the NYSE American LLC, the expected use of proceeds, and the expected date of closing of the Offering. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.
For Investor Relations Inquiries
Arie Gordashnikov
arie@shimony.com
+972-3-6116629
FAQ
When will Regentis Biomaterials (RGNT) begin trading on the NYSE American?
How many shares did Regentis (RGNT) offer and at what price?
What will Regentis (RGNT) use the IPO proceeds for?
Is there a potential for additional shares after the RGNT IPO?
When is the RGNT offering expected to close?
